ACURX PHARMACEUTICALS INC (ACXP) Stock Price, Quote, News and Overview
NASDAQ:ACXP - Nasdaq - US00510M1045 - Common Stock - Currency: USD
ACXP Quote, Performance and Key Statistics
0.8207
+0.51 (+167.24%)
The current stock price of ACXP is 0.8207 USD. In the past month the price increased by 102.59%. In the past year, price decreased by -64.78%.
ACXP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.06 | 327.63B | ||
| AMGN | AMGEN INC | 13.97 | 155.96B | ||
| GILD | GILEAD SCIENCES INC | 13.95 | 134.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.50B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.48 | 54.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.25B | ||
| ARGX | ARGENX SE - ADR | 94.04 | 33.02B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.5 | 27.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 22.88B | ||
| BIIB | BIOGEN INC | 8 | 18.54B | ||
| INSM | INSMED INC | N/A | 18.26B |
Related stock screener links
About ACXP
Company Profile
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
Company Info
ACURX PHARMACEUTICALS INC
259 Liberty Avenue
Staten Island NEW YORK US
CEO: David P. Luci
Employees: 4
Phone: 19175331469
ACURX PHARMACEUTICALS INC / ACXP FAQ
What is the stock price of ACURX PHARMACEUTICALS INC today?
The current stock price of ACXP is 0.8207 USD. The price increased by 167.24% in the last trading session.
What is the ticker symbol for ACURX PHARMACEUTICALS INC stock?
The exchange symbol of ACURX PHARMACEUTICALS INC is ACXP and it is listed on the Nasdaq exchange.
On which exchange is ACXP stock listed?
ACXP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACURX PHARMACEUTICALS INC stock?
9 analysts have analysed ACXP and the average price target is 5.81 USD. This implies a price increase of 608.11% is expected in the next year compared to the current price of 0.8207. Check the ACURX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACURX PHARMACEUTICALS INC worth?
ACURX PHARMACEUTICALS INC (ACXP) has a market capitalization of 19.27M USD. This makes ACXP a Nano Cap stock.
How many employees does ACURX PHARMACEUTICALS INC have?
ACURX PHARMACEUTICALS INC (ACXP) currently has 4 employees.
Should I buy ACURX PHARMACEUTICALS INC (ACXP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACXP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACXP, evaluating the profitability, health, valuation and growth aspects
- ACURX PHARMACEUTICALS INC (ACXP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACURX PHARMACEUTICALS INC (ACXP) Sales and EPS estimates to see what analysts future expectations are.
- ACURX PHARMACEUTICALS INC (ACXP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACURX PHARMACEUTICALS INC (ACXP) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACURX PHARMACEUTICALS INC (ACXP) Stock Chart to make your own analysis
- ACURX PHARMACEUTICALS INC (ACXP) Latest news and press-releases to stay up to date.
Does ACURX PHARMACEUTICALS INC (ACXP) stock pay dividends?
ACXP does not pay a dividend.
When does ACURX PHARMACEUTICALS INC (ACXP) report earnings?
ACURX PHARMACEUTICALS INC (ACXP) will report earnings on 2025-08-07.
What is the Price/Earnings (PE) ratio of ACURX PHARMACEUTICALS INC (ACXP)?
ACURX PHARMACEUTICALS INC (ACXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
What is the Short Interest ratio of ACURX PHARMACEUTICALS INC (ACXP) stock?
The outstanding short interest for ACURX PHARMACEUTICALS INC (ACXP) is 1.41% of its float. Check the ownership tab for more information on the ACXP short interest.
ACXP Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ACXP. When comparing the yearly performance of all stocks, ACXP is one of the better performing stocks in the market, outperforming 81.41% of all stocks.
ACXP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ACXP. The financial health of ACXP is average, but there are quite some concerns on its profitability.
ACXP Financial Highlights
Over the last trailing twelve months ACXP reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 40.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -247.1% | ||
| ROE | -513.73% | ||
| Debt/Equity | 0 |
ACXP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ACXP. The Buy consensus is the average rating of analysts ratings from 9 analysts.